These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27087977)

  • 21. SBRT for oligoprogressive oncogene addicted NSCLC.
    Basler L; Kroeze SG; Guckenberger M
    Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
    Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U
    J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
    Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic ablative radiotherapy for oligometastatic disease in liver.
    Kim M; Son SH; Won YK; Kay CS
    Biomed Res Int; 2014; 2014():340478. PubMed ID: 24868526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery?
    Renaud S; Falcoz PE; Olland A; Massard G
    Interact Cardiovasc Thorac Surg; 2013 Jan; 16(1):68-73. PubMed ID: 23054908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?
    Ratnakumaran R; McDonald F
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):753-760. PubMed ID: 36117126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer.
    Giraud N; Abdiche S; Trouette R
    Cancer Radiother; 2019 Jul; 23(4):346-354. PubMed ID: 31130373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
    Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Extracranial stereotactic radiotherapy for early-stage non-small cell lung cancer and oligometastases].
    Riesterer O
    Praxis (Bern 1994); 2013 Oct; 102(21):1309-16. PubMed ID: 24129299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.
    Ni J; Li G; Yang X; Chu L; Wang J; Li Y; Zou L; Li Y; Xie C; Zhu Z
    Radiat Oncol; 2019 Mar; 14(1):44. PubMed ID: 30866974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
    Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
    J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy for oligometastases.
    Tree AC; Khoo VS; Eeles RA; Ahmed M; Dearnaley DP; Hawkins MA; Huddart RA; Nutting CM; Ostler PJ; van As NJ
    Lancet Oncol; 2013 Jan; 14(1):e28-37. PubMed ID: 23276369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Jairam V; Park HS; Decker RH
    Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic strategies in advanced ALK positive non-small cell lung cancer].
    Tiotiu A; Billon Y; Vaillant P; Menard O; Hofman P; Mascaux C
    Rev Mal Respir; 2019 Dec; 36(10):1107-1116. PubMed ID: 31727555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.